Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea

NCT02385240 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

552

Enrollment

INDUSTRY

Sponsor class

Conditions

Rosacea

Interventions

DRUG: Brimonidine Topical Gel, 0.33 percent (Perrigo)
DRUG: Brimonidine Topical Gel, 0.33 percent (Reference)
DRUG: Placebo gel

Sponsor

Padagis LLC